American Pharmacy News Reports Stories

Prime's health insurance guide urges people to enroll or otherwise pay steep penalties.

Prime Therapeutics has released a guide on how to enroll in health insurance to avoid tax penalties. Read More »

Prime releases autoimmune drug cost report

Autoimmune drugs are among the most expensive in the industry.

Prime Therapeutics has released a report detailing the rising cost of autoimmune drugs. Read More »

Military pharmacies focal point for APhA seminar

JFPS 2016 was held at the Gaylord National Hotel and Convention Center in Oxon Hill, Maryland.

The American Pharmacists Association recently hosted 650 pharmacists at its 2016 Joint Federal Pharmacy Seminar in Oxon Hill, Maryland. Read More »

Janssen to present XARELTO trial results

The presentation will take place at the AHA Scientific Sessions.

Janssen Pharmaceuticals Inc.'s results of its XARELTO Phase 3b PIONEER AF-PCI clinical trial and new research involving INVOKANA will be featured in presentations at the American Heart Association Scientific Sessions, being held through Wednesday in New Orleans. Read More »

Step therapies are cutting drug costs, but impact is controversial

John Breslin | Nov 13, 2016

David Howard argued that patient-assistance programs may lead to higher drug prices as a result of the interplay between patient demand and prices.

In the dance between drug and insurance companies over the cost of medicines and which ones should be prescribed, step therapy or “fail first” policies are increasingly popular. Read More »

OFIRMEV approved for Prior Approval Supplement

OFIREMEV will now be available in an intravenous bag.

Mallinckrodt Pharmaceuticals' OFIRMEV injection has received a Prior Approval Supplement from the U.S. Food and Drug Administration. Read More »

Walgreens honored by American Ireland Fund

Walgreens Boots Alliance won the American Ireland Fund Corporate Social Responsibility Award.

Walgreens Boots Alliance Inc. was recently honored by the American Ireland Fund at the 32nd Annual Chicago Dinner by awarding it with the American Ireland Fund Corporate Social Responsibility Award. Read More »

Innovus, Elis finalize Zestra agreement

The agreement gives Elis exclusive licensing to Zestra.

Innovus Pharmaceuticals and Elis Pharmaceuticals have finalized a second exclusive license and distribution agreement for Zestra. Read More »

FDA approves VENTANA ALK (D5F3) CDx Assay

The VENTANA ALK (D5F3) CDx Assay is a diagnostic companion that is used to identify patients with ALK-positive lung cancer.

Roche's VENTANA ALK (D5F3) CDx Assay has received approval from the U.S. Food and Drug Administration to be used in conjunction with the VENTANA BenchMark ULTRA automated slide stainer. Read More »

Bayer submits Stivarga sNDA to FDA

The FDA will review the sNDA and make a final ruling on Stivarga tablets.

Bayer has submitted its supplemental New Drug Application for Stivarga tablets to the U.S. Food and Drug Administration. Read More »

Bears running back joins fight against PF

Jordan Howard, the leading rusher for the Chicago Bears, attended the 2016 Pulmonary Fibrosis Foundation’s volunteer meeting where he dedicated himself to fighting pulmonary fibrosis. Read More »

FDA approves Propeller system for use with Ellipta inhaler

The U.S. Food and Drug Administration has approved Propeller Health's platform for use with GSK’s Ellipta inhaler. Read More »

NPC Board of Directors taps Ofman as vice chair

Dr. Joshua Ofman becomes the vice chairman after serving on the Board for four years.

The National Pharmaceutical Council Board of Directors has appointed Dr. Joshua Ofman as its new vice chairman. Read More »

Abbvie’s valiparib granted Orphan Drug Designation

AbbVie's oral poly polymerase inhibitor valiparib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »

FDA accepts BLA for human anti-rabies lgG therapy

The FDA will review the BLA by August 29, 2017.

Kedrion Biopharma and Kamada's Biologics License Application for human anti-rabies immunoglobulin therapy has been accepted for review by the U.S. Food and Drug Administration. Read More »

Eli Lilly to present baricitinib data at ARHP Annual Meeting

This trial assessed the ability of Taltz to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis.

Eli Lilly and Co.'s analysis of its Phase 3 baricitinib trial efficiency and safety data, as well as that of other Phase 2 trials, will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting, which is being held on Nov. 11-16 in Washington, D.C. Read More »

HalioDx reports progress on clinical research services

This year, HalioDx has finalized seven master service agreements with biopharmaceutical companies.

HalioDx SAS has released a report detailing the progress being made by its clinical research services. Read More »

CVS Caremark receives trio of accreditations from URAC

CVS Health has shown its overall dedication to quality care, the improvement of processes and better outcomes for its patients.

URAC has accredited CVS Caremark's Pharmacy Adviser counseling program run by the Health Call Center and its Pharmacy Benefit Management and Drug Therapy Management. Read More »

ACADIA initiates ENHANCE-1 trial for antipsychotic care

The current antipsychotic medications on the market used to treat schizophrenia focus on targeting the dopaminergic pathway.

ACADIA Pharmaceuticals' ENHANCE-1 Phase III trial involving pimavanserin has been initiated to assess the ability of pimavanserin to treat schizophrenia in patients who have had a negative response to the antipsychotic therapies currently in use. Read More »

Anthera to present BRIGHT-SC data at Kidney Week meeting